Ocata Therapeutics Stock Price, News & Analysis (NASDAQ:OCAT)

$8.47 0.01 (0.12 %)
(As of 11/20/2017 12:07 PM ET)
Previous Close$8.46
Today's Range$8.45 - $8.48
52-Week Range$3.06 - $8.71
Volume1.12 million shs
Average Volume656,469 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Ocata Therapeutics (NASDAQ:OCAT)

Ocata Therapeutics logoOcata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: N/A
  • Symbol: NASDAQ:OCAT
  • Previous Symbol: OTCMKTS:ACTC
  • CUSIP: N/A
  • Web: www.ocata.com
Profitability:
  • Trailing EPS: ($0.70)
  • Net Margins: -4,564.66%
  • Return on Equity: -103.02%
  • Return on Assets: -46.18%
Misc:
  • Outstanding Shares: 42,230,000
 

Frequently Asked Questions for Ocata Therapeutics (NASDAQ:OCAT)

What is Ocata Therapeutics' stock symbol?

Ocata Therapeutics trades on the NASDAQ under the ticker symbol "OCAT."

How were Ocata Therapeutics' earnings last quarter?

Ocata Therapeutics Inc (NASDAQ:OCAT) posted its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The biotechnology company earned $0.04 million during the quarter. Ocata Therapeutics had a negative return on equity of 103.02% and a negative net margin of 4,564.66%. View Ocata Therapeutics' Earnings History.

Who are some of Ocata Therapeutics' key competitors?

How do I buy Ocata Therapeutics stock?

Shares of Ocata Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocata Therapeutics' stock price today?

One share of Ocata Therapeutics stock can currently be purchased for approximately $8.47.

How can I contact Ocata Therapeutics?

Ocata Therapeutics' mailing address is 33 Locke Dr, MARLBOROUGH, MA 01752-1167, United States. The biotechnology company can be reached via phone at +1-508-7561212.


MarketBeat Community Rating for Ocata Therapeutics (NASDAQ OCAT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  76
MarketBeat's community ratings are surveys of what our community members think about Ocata Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Ocata Therapeutics (NASDAQ:OCAT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Ocata Therapeutics (NASDAQ:OCAT)

Price Target History for Ocata Therapeutics (NASDAQ:OCAT)

Analysts' Ratings History for Ocata Therapeutics (NASDAQ:OCAT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/23/2016Cantor FitzgeraldReiterated RatingHold$8.50N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Ocata Therapeutics (NASDAQ:OCAT)

Earnings by Quarter for Ocata Therapeutics (NASDAQ:OCAT)

Earnings History by Quarter for Ocata Therapeutics (NASDAQ OCAT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2015Q215($0.19)($0.20)$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocata Therapeutics (NASDAQ:OCAT)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ocata Therapeutics (NASDAQ:OCAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ocata Therapeutics (NASDAQ OCAT)

Insider Trades by Quarter for Ocata Therapeutics (NASDAQ:OCAT)
Insider Trades by Quarter for Ocata Therapeutics (NASDAQ:OCAT)

Insider Trades by Quarter for Ocata Therapeutics (NASDAQ OCAT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2015Robert LanzainsiderSell35,000$8.31$290,850.00View SEC Filing  
7/7/2014Robert LanzaInsiderSell1,500,000$0.08$120,000.00View SEC Filing  
1/10/2013Gary H RabinCEOSell12,115,963$0.12$1,453,915.56View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocata Therapeutics (NASDAQ OCAT)

Source:
DateHeadline
Astellas sues former research partners, claiming usurpation of stem cell tech - Boston Business JournalAstellas sues former research partners, claiming 'usurpation' of stem cell tech - Boston Business Journal
www.bizjournals.com - November 14 at 9:01 PM
Reviewing Ocata Therapeutics (OCAT) and Madrigal Pharmaceuticals (MDGL)Reviewing Ocata Therapeutics (OCAT) and Madrigal Pharmaceuticals (MDGL)
www.americanbankingnews.com - November 12 at 1:10 AM
Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology - PR Newswire (press release)Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology - PR Newswire (press release)
www.prnewswire.com - October 21 at 7:19 AM
How Flagships newest startup is pursuing a holy grail of biotech - Boston Business JournalHow Flagship's newest startup is pursuing a 'holy grail' of biotech - Boston Business Journal
www.bizjournals.com - June 23 at 8:42 AM
Flagship Pioneering Launches Sigilon Therapeutics to Advance Afibromer™ Encapsulated Cell Therapies - PR Newswire (press release)Flagship Pioneering Launches Sigilon Therapeutics to Advance Afibromer™ Encapsulated Cell Therapies - PR Newswire (press release)
www.prnewswire.com - June 22 at 6:08 AM
Global Regenerative Medicine Market Analysis & Forecast 2017-2021 - Research and MarketsGlobal Regenerative Medicine Market Analysis & Forecast 2017-2021 - Research and Markets
www.bizjournals.com - May 5 at 7:14 PM
Pharma CEO Hunts New Trophy After Prostate Cancer Blockbuster ... - BloombergPharma CEO Hunts New Trophy After Prostate Cancer Blockbuster ... - Bloomberg
www.bloomberg.com - December 1 at 12:08 AM
Pharma CEO Hunts New Trophy After Prostate Cancer BlockbusterPharma CEO Hunts New Trophy After Prostate Cancer Blockbuster
www.bloomberg.com - November 30 at 11:50 AM
BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016 - Business Wire (press release)BioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016 - Business Wire (press release)
www.businesswire.com - November 10 at 6:24 PM
Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen - TheStreet.comApplied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen - TheStreet.com
www.thestreet.com - September 20 at 11:49 AM
Chinese biotech Vcanbio opens first U.S. subsidiaries in Natick - Boston Business Journal (blog)Chinese biotech Vcanbio opens first U.S. subsidiaries in Natick - Boston Business Journal (blog)
www.bizjournals.com - September 13 at 11:24 AM
Pharma Leader Series: Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and AsiaPharma Leader Series: Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and Asia
www.bizjournals.com - September 6 at 11:18 AM
Key Executives for Ocata Therapeutics, Inc.Key Executives for Ocata Therapeutics, Inc.
www.bloomberg.com - August 23 at 6:47 PM
Ocata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate - Seeking AlphaOcata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate - Seeking Alpha
seekingalpha.com - January 26 at 2:31 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Ocata Therapeutics (NASDAQ OCAT) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.